ACTUATE THERAPEUTICS, INC.
ACTUDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
9-ING-41
Cancer
FOLFIRNINOX
Pancreatic Adenocarcinoma
Carboplatin
Salivary Gland Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
9-ING-41 | Phase 2 | Cancer | - | - |
FOLFIRNINOX | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Carboplatin | Phase 2 | Salivary Gland Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ACTUATE THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ACTUATE THERAPEUTICS, INC.'s (ACTU) pipeline across Phase 2. Its lead program is 9-ING-41 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACTUATE THERAPEUTICS, INC.'s next FDA catalyst?→
ACTUATE THERAPEUTICS, INC.'s (ACTU) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACTU biotech catalysts?→
Add ACTU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACTUATE THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.